Cancer antigens targeted by drug conjugates are restricted to the few membrane receptors (such as HER2 and TROP2) that ...
XYone Therapeutics, Inc. ("XYone"), a clinical-stage biotechnology company, announced that the first patient has been dosed in the first-in-human Phase 1b/2 clinical trial of XYA02(also known as ...
Lung cancer remains the deadliest malignancy worldwide, and non-small cell lung cancer (NSCLC) accounts for roughly 85 ...
Phase 3 trial data support tambotatug pelitecan as a new second-line treatment for patients with relapsed small-cell lung cancer – a group with few existing treatment options.
FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases HONG KONG and SHANGHAI and ...
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, will invest $2 billion in Summit Therapeutics Inc ...
AstraZeneca will invest $2 billion in Summit Therapeutics convertible preferred shares, with Summit stock up more than 17% ...
The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but ...
6hon MSN
Summit Therapeutics soars nearly 20% after AstraZeneca bets $2 billion on cancer drug Ivonescimab
Shares of Summit Therapeutics Inc. (NASDAQ: SMMT) surged about 20% premarket on Tuesday after AstraZeneca Plc (NYSE: AZN) ...
Sept 28 (Reuters) - Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the ...
AstraZeneca ( AZN) has agreed to make a $2 billion strategic equity investment in Summit Therapeutics ( SMMT) while launching a clinical collaboration aimed at advancing new cancer treatment ...
Washington has announced that select speciality medications and related components originating from India and 19 other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results